J. Goldman & Co’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

J. Goldman & Co’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.55M	Buy	20,000 +10,000	+100%	+$1.25M	0.07%	284
2025 Q4	$1.22M	Buy	+10,000	New	+$1.15M	0.03%	363
2025 Q2	–	Sell	-20,000	Closed	-$1.62M	–	662
2025 Q1	$1.62M	Hold	20,000	–	–	0.04%	320
2024 Q4	$1.8M	Buy	+20,000	New	+$1.94M	0.05%	282
2023 Q4	–	Sell	-17,500	Closed	-$1.28M	–	491
2023 Q3	$1.28M	Sell	17,500 -42,500	-71%	-$3.39M	0.04%	227
2023 Q2	$4.99M	Buy	+60,000	New	+$5.02M	0.18%	135
2017 Q4	–	Sell	-65,000	Closed	-$5.63M	–	449
2017 Q3	$5.63M	Buy	65,000 +26,000	+67%	+$2.08M	0.28%	103
2017 Q2	$3.01M	Buy	+39,000	New	+$2.77M	0.16%	147
2016 Q2	–	Sell	-100,000	Closed	-$5.17M	–	415
2016 Q1	$5.17M	Buy	+100,000	New	+$5.19M	0.32%	90

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

J. Goldman & Co's XBI Position: Q1 2026 in Review

J. Goldman & Co opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q1 2026: 2,000 shares worth $255K. The stake represents 0.01% of the portfolio and ranks #580 among its holdings. This is a return to the name: J. Goldman & Co previously reported a position in XBI as recently as Q4 2024.

J. Goldman & Co first reported a position in XBI in Q4 2017 and has held it in 8 quarters since. The position peaked at $1.52M in Q4 2024. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

J. Goldman & Co held 2,000 shares of State Street SPDR S&P Biotech ETF worth $255K as of Q1 2026.
State Street SPDR S&P Biotech ETF was a new J. Goldman & Co position in Q1 2026.
State Street SPDR S&P Biotech ETF made up 0.01% of J. Goldman & Co's portfolio in Q1 2026, its #580 holding.
J. Goldman & Co first reported a position in State Street SPDR S&P Biotech ETF in Q4 2017 and has held it in 8 quarters since.
J. Goldman & Co's State Street SPDR S&P Biotech ETF position peaked at $1.52M in Q4 2024.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.